Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ADMA

ADMA - ADMA Biologics Inc Stock Price, Fair Value and News

13.74USD+0.35 (+2.61%)Market Closed

Market Summary

ADMA
USD13.74+0.35
Market Closed
2.61%

ADMA Alerts

  • 1 major insider sales recently.

ADMA Stock Price

View Fullscreen

ADMA RSI Chart

ADMA Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

-874.03

Price/Sales (Trailing)

11.25

EV/EBITDA

119.48

Price/Free Cashflow

197.44

ADMA Price/Sales (Trailing)

ADMA Profitability

Operating Margin

39.39%

EBT Margin

-6.35%

Return on Equity

-2.37%

Return on Assets

-1.04%

Free Cashflow Yield

0.51%

ADMA Fundamentals

ADMA Revenue

Revenue (TTM)

283.2M

Rev. Growth (Yr)

43.86%

Rev. Growth (Qtr)

10.79%

ADMA Earnings

Earnings (TTM)

-3.6M

Earnings Growth (Yr)

362.28%

Earnings Growth (Qtr)

200.92%

Breaking Down ADMA Revenue

Last 7 days

14.9%

Last 30 days

29.3%

Last 90 days

127.5%

Trailing 12 Months

282.7%

How does ADMA drawdown profile look like?

ADMA Financial Health

Current Ratio

5.21

ADMA Investor Care

Shares Dilution (1Y)

4.29%

Diluted EPS (TTM)

-0.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024283.2M000
2023181.9M208.1M234.3M258.2M
2022122.6M138.7M159.1M154.1M
202148.1M58.1M68.5M109.6M
202036.2M37.0M40.1M42.2M
201916.5M18.8M21.8M29.6M
201824.2M25.4M24.9M17.0M
201711.2M12.3M14.1M22.8M
20167.8M8.8M9.8M10.7M
20155.9M5.7M6.2M7.2M
20143.8M4.6M4.9M5.9M
20131.9M2.4M3.2M3.1M
20121.7M1.5M1.3M1.1M
20110001.9M
20100000
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ADMA Biologics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 30, 2024
kestenberg-messina kaitlin m.
sold (taxes)
-23,310
11.18
-2,085
coo and svp, compliance
Jun 30, 2024
grossman adam s
sold (taxes)
-243,187
11.18
-21,752
president,ceo, and interim cfo
Jun 14, 2024
grossman adam s
gifted
-
-
-10,000
president,ceo, and interim cfo
Jun 14, 2024
grossman adam s
sold
-1,476,600
3.21
-460,000
president,ceo, and interim cfo
Jun 14, 2024
grossman adam s
sold
-1,071,980
10.7198
-100,000
president,ceo, and interim cfo
Apr 01, 2024
kestenberg-messina kaitlin m.
acquired
-
-
192,320
coo and svp, compliance
Mar 31, 2024
kestenberg-messina kaitlin m.
sold (taxes)
-13,761
6.6
-2,085
coo and svp, compliance
Mar 31, 2024
grossman adam s
sold (taxes)
-143,563
6.6
-21,752
president,ceo, and interim cfo
Mar 19, 2024
elms steve
sold
-2,503,920
6.08
-411,829
-
Mar 18, 2024
elms steve
sold
-299,821
6.01
-49,887
-

1–10 of 50

Which funds bought or sold ADMA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 15, 2024
Signature Wealth Management Partners, LLC
unchanged
-
46,716
114,036
0.09%
Jul 15, 2024
ROMAN BUTLER FULLERTON & CO
new
-
378,060
378,060
0.12%
Jul 12, 2024
SG Americas Securities, LLC
added
3,084
3,992,000
4,067,000
0.02%
Jul 12, 2024
USA FINANCIAL FORMULAS
new
-
70,188
70,188
0.01%
Jul 12, 2024
INSPIRION WEALTH ADVISORS, LLC
unchanged
-
54,960
134,160
0.02%
Jul 10, 2024
CWM, LLC
added
114
67,000
92,000
-%
Jul 10, 2024
Simplicity Wealth,LLC
reduced
-1.46
45,738
114,081
-%
Jul 10, 2024
Prism Advisors, Inc.
sold off
-100
-128,066
-
-%
Jul 09, 2024
ADIRONDACK TRUST CO
unchanged
-
2,679
6,540
-%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
added
5.45
256,000
730,000
-%

1–10 of 49

Are Funds Buying or Selling ADMA?

Are funds buying ADMA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADMA
No. of Funds

Unveiling ADMA Biologics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
teachers advisors, llc
2.17%
4,955,411
SC 13G/A
Mar 11, 2024
tiaa cref investment management llc
2.17%
4,955,411
SC 13G/A
Mar 11, 2024
nuveen asset management, llc
2.17%
4,955,411
SC 13G/A
Feb 14, 2024
nuveen asset management, llc
2.24%
5,062,545
SC 13G
Feb 14, 2024
teachers advisors, llc
2.24%
5,062,545
SC 13G
Feb 14, 2024
tiaa cref investment management llc
2.24%
5,062,545
SC 13G
Feb 14, 2024
perceptive advisors llc
2.8%
6,433,369
SC 13G/A
Feb 13, 2024
vanguard group inc
5.71%
12,891,875
SC 13G
Jan 26, 2024
blackrock inc.
7.9%
17,917,745
SC 13G/A
Feb 14, 2023
nuveen asset management, llc
2.48%
5,483,369
SC 13G/A

Recent SEC filings of ADMA Biologics Inc

View All Filings
Date Filed Form Type Document
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jun 28, 2024
8-K
Current Report
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 04, 2024
8-K
Current Report
May 17, 2024
8-K
Current Report
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
Apr 15, 2024
DEFA14A
DEFA14A

Peers (Alternatives to ADMA Biologics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
48.0B
6.8B
-10.56% 2.15%
-8.04
7.01
-64.45% -224.75%
31.6B
2.0B
55.73% 23.15%
-95.14
15.77
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.3B
2.5B
2.83% -0.92%
79.36
6.6
13.74% 186.89%
14.4B
3.8B
3.06% 4.80%
19.28
3.81
8.58% 129.81%
MID-CAP
5.5B
107.9M
4.99% -8.71%
-10.01
48.09
54.84% -28.31%
5.0B
524.1M
-2.02% -21.56%
-11.97
9.53
394.93% 39.61%
4.0B
251.0M
15.33% 15.88%
-13.61
16.07
73.58% -86.73%
3.7B
240.7M
14.36% -14.84%
-7.76
12.77
-1.03% -213.92%
3.1B
813.8M
24.88% -44.36%
-1.8K
3.78
56.43% 98.83%
2.3B
996.6M
14.03% 101.23%
-5.78
2.31
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
12.68% 25.98%
30.78
4.87
60.38% -34.49%
644.1M
881.7K
20.30% 675.68%
-19.08
481.06
-77.61% 33.36%
288.6M
4.2M
22.55% 71.91%
-2.31
69.39
-66.30% 48.24%
18.5M
2.1M
-16.02% -80.80%
-0.8
7.61
-13.45% 69.54%

ADMA Biologics Inc News

Latest updates
MarketBeat10 hours ago
American Banking and Market News11 Jul 202405:25 am

ADMA Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue10.8%81,87573,90367,27560,12356,91449,98241,09033,90529,10355,00020,68117,83116,04913,95610,2767,78810,20011,8187,2237,0003,529
Cost Of Revenue-0.1%42,76742,81742,62243,43340,40135,80531,43326,13625,44122,87220,29518,83317,77019,11111,85513,49616,82911,6927,91610,4919,405
Gross Profit25.8%39,10831,08624,65316,69016,51314,1779,6577,7693,6623,511385-1,002-1,721--------
Operating Expenses2.6%17,28716,85315,96717,16317,32620,23518,97316,94418,47716,70314,82214,57913,443-30,11524,07724,91126,97019,86416,27317,90016,737
  S&GA Expenses0.7%15,63915,53514,72614,24814,51213,89512,89311,97013,70011,69810,72710,43810,0349,3009,1168,7037,9327,0327,1976,0865,595
  R&D Expenses1.0%4504465961,4038551,0751,0428736247297711,1599881,0131,7081,6561,529465491517871
EBITDA Margin-22.2%0.05*0.06*0.06*0.07*0.06*0.05*0.04*0.02*0.01*0.01*0.00*----------
Interest Expenses-39.4%3,7696,2156,3986,2996,1155,7375,5804,5733,3893,3163,2993,2473,1963,1093,0913,0672,7172,7312,6492,0731,541
Income Taxes-595--------------------
Earnings Before Taxes-18,401----6,789----------------
EBT Margin8.8%-0.06*-0.07*-0.08*-0.09*-0.10*-0.12*-0.11*-0.13*-0.15*-0.16*-0.26*----------
Net Income200.9%17,806-17,6442,565-6,370-6,789-12,231-14,899-13,764-25,007-16,649-17,712-18,905-18,379-19,407-16,917-20,178-19,245-10,561-11,438-13,211-13,067
Net Income Margin88.2%-0.01*-0.11*-0.10*-0.19*-0.26*-0.43*-0.44*-0.53*-0.64*-0.65*-1.09*-1.27*---------
Free Cashflow-127.8%-4,56516,39911,229-6,931-16,666-11,127-16,665-16,770-28,855-37,140-16,201-36,737---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets6.6%35132934934334134830129730827623923323620819019221112713814378.00
  Current Assets7.6%27625727426626427022422324020917517117715414014316586.0097.0010438.00
    Cash Equivalents-11.7%45.0051.0074.0063.0069.0087.0035.0052.0070.0051.0034.0042.0062.0056.0060.0076.0010127.0048.0074.0017.00
  Inventory2.8%17817316316216416316314613912511410094.0082.0070.0056.0052.0053.0040.0024.0018.00
  Net PPE2.8%55.0054.0055.0056.0057.0058.0057.0055.0053.0051.0048.0046.0044.0042.0040.0037.0035.0032.0031.0029.0030.00
  Goodwill0%4.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.00
Liabilities1.6%19719419819619519620018318113513612112311911911511410110296.0068.00
  Current Liabilities6.6%53.0050.0042.0042.0037.0039.0044.0028.0032.0030.0032.0018.0021.0020.0016.0013.0014.0014.0015.0010.008.00
  Long Term Debt----------------------
Shareholder's Equity13.7%15413515114714615210011412714110311211388.0071.0077.0096.0026.0036.0047.0010.00
  Retained Earnings3.5%-488-506-488-491-484-478-465-450-437-412-395-377-358-340-321-304-283-264-254-242-229
  Additional Paid-In Capital0.1%642641640638630630566565564553498489471429392381380291290290240
Shares Outstanding2.5%232226226225222222196196196140134127116--------
Float----794---373---173---184-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-112.6%-2,21817,59611,985-6,058-14,723-7,379-13,284-12,830-26,013-33,465-13,412-32,262-33,229-32,219-23,852-21,284-24,646-19,652-23,630-18,623-14,287
  Share Based Compensation22.7%2,1411,7451,6951,6371,1101,0691,3131,1911,6411,213688805781688775716677636651727637
Cashflow From Investing-67.8%-2,362-1,407-756-872-1,945-3,748-3,380-3,940-2,842-3,675-2,788-4,475-2,571-3,598-2,885-4,168-2,072-1,594-1,971-135-110
Cashflow From Financing96.3%-1,447-38,993415240-65062,744-843-31947,27153,8198,20317,18141,84532,06410,631-1.69101,203-7.68-7.5675,8414,177
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ADMA Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]  
REVENUES$ 81,875$ 56,914
Cost of product revenue42,76740,401
Gross profit39,10816,513
OPERATING EXPENSES:  
Research and development450855
Plasma center operating expenses1,0051,780
Amortization of intangible assets193179
Selling, general and administrative15,63914,512
Total operating expenses17,28717,326
INCOME (LOSS) FROM OPERATIONS21,821(813)
OTHER INCOME (EXPENSE):  
Interest income384166
Interest expense(3,769)(6,115)
Other expense(35)(27)
Other expense, net(3,420)(5,976)
INCOME (LOSS) BEFORE INCOME TAXES18,401(6,789)
Provision for income taxes5950
NET INCOME (LOSS)$ 17,806$ (6,789)
BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)$ 0.08$ (0.03)
DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)$ 0.08$ (0.03)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:  
Basic (in shares)228,874,847221,921,750
Diluted (in shares)236,414,374221,921,750

ADMA Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 45,325$ 51,352
Accounts receivable, net49,62127,421
Inventories177,732172,906
Prepaid expenses and other current assets3,7415,334
Total current assets276,419257,013
Property and equipment, net55,31753,835
Intangible assets, net321499
Goodwill3,5303,530
Right-to-use assets9,3979,635
Deposits and other assets5,8914,670
TOTAL ASSETS350,875329,182
Current liabilities:  
Accounts payable17,18615,660
Accrued expenses and other current liabilities33,69132,919
Current portion of deferred revenue1,118182
Current portion of lease obligations1,0931,045
Total current liabilities53,08849,806
Senior notes payable, net of discount130,847130,594
Deferred revenue, net of current portion1,6541,690
End of term fee1,6881,688
Lease obligations, net of current portion9,4879,779
Other non-current liabilities405419
TOTAL LIABILITIES197,169193,976
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY  
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding00
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 231,769,765 and 226,063,032 shares issued and outstanding at March 31, 2024 and December 31, 20232323
Additional paid-in capital642,133641,439
Accumulated deficit(488,450)(506,256)
TOTAL STOCKHOLDERS' EQUITY153,706135,206
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 350,875$ 329,182
ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
 CEO
 WEBSITEadmabiologics.com
 INDUSTRYBiotechnology
 EMPLOYEES617

ADMA Biologics Inc Frequently Asked Questions


What is the ticker symbol for ADMA Biologics Inc? What does ADMA stand for in stocks?

ADMA is the stock ticker symbol of ADMA Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ADMA Biologics Inc (ADMA)?

As of Tue Jul 16 2024, market cap of ADMA Biologics Inc is 3.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers. The fair value of ADMA Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ADMA Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ADMA Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ADMA is over valued or under valued. Whether ADMA Biologics Inc is cheap or expensive depends on the assumptions which impact ADMA Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMA.

What is ADMA Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jul 16 2024, ADMA's PE ratio (Price to Earnings) is -874.03 and Price to Sales (PS) ratio is 11.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ADMA Biologics Inc's stock?

In the past 10 years, ADMA Biologics Inc has provided 0.031 (multiply by 100 for percentage) rate of return.